DLBCL

1 stories · following the connections

Business

Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China

By Nasdaq OMXNov 29, 2016, 12:16 PM UTC